drugset / Trial / NCT00659321

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

NCT00659321

RandomizedParallel-groupTriple-blindTreatment

Summary

Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome. Nicotine acid decreases postprandial hyperlipidaemia in patients with metabolic syndrome which reduces the low-grade inflammation and the risk of atherosclerosis.

Timeline

Start
2007-01
Primary completion
2008-09
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator nicotine acid Unknown 1500 mg